How to buy Ironwood Pharmaceuticals stock (IRWD)

Ironwood Pharmaceuticals is a drug manufacturers - specialty & generic business based in the US. Ironwood Pharmaceuticals shares (IRWD) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $4.45 – an increase of 26.06% over the previous week. Ironwood Pharmaceuticals employs 267 staff and has a trailing 12-month revenue of around $378.4 million.

Our top picks for where to buy Ironwood Pharmaceuticals stock

Buy Ironwood Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Ironwood Pharmaceuticals stock price (NASDAQ: IRWD)

Use our graph to track the performance of IRWD stocks over time.

Ironwood Pharmaceuticals shares at a glance

• Key figures

Information last updated 2024-12-18.

Latest market close	$4.45
52-week range	$3.06 - $15.70
50-day moving average more info button	$4.00
200-day moving average more info button	$5.84
Wall St. target price	$12.50
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-0.01

Is it a good time to buy Ironwood Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Ironwood Pharmaceuticals price performance over time

Historical closes compared with the close of $3.88 from 2024-12-19

1 week (2024-12-13)	9.92%
1 month (2024-11-22)	12.79%
3 months (2024-09-20)	-9.77%
6 months (2024-06-21)	-36.29%

1 year (2023-12-21)	-65.05%
2 years (2022-12-21)	-68.35%
3 years (2021-12-21)	11.43
5 years (2019-12-20)	13.66

Is Ironwood Pharmaceuticals stock undervalued or overvalued?

Valuing Ironwood Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Ironwood Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Ironwood Pharmaceuticals's EBITDA

Ironwood Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $97.4 million.

The EBITDA is a measure of a Ironwood Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Ironwood Pharmaceuticals financials

Revenue TTM	$378.4 million
Operating margin TTM	28.01%
Gross profit TTM	$366.3 million
Return on assets TTM	13.05%
Return on equity TTM	-574.72%
Profit margin	-0.65%
Book value	$-1.95
Market Capitalization more info button	$553.7 million

TTM: trailing 12 months

Ironwood Pharmaceuticals share dividends

We're not expecting Ironwood Pharmaceuticals to pay a dividend over the next 12 months.

Have Ironwood Pharmaceuticals's shares ever split?

Ironwood Pharmaceuticals's shares were split on a 1194:1000 basis on 1 April 2019 . So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1194 shares. This wouldn't directly have changed the overall worth of your Ironwood Pharmaceuticals shares – just the quantity. However, indirectly, the new 16.2% lower share price could have impacted the market appetite for Ironwood Pharmaceuticals shares which in turn could have impacted Ironwood Pharmaceuticals's share price.

Ironwood Pharmaceuticals share price volatility

Over the last 12 months, Ironwood Pharmaceuticals's shares have ranged in value from as little as $3.06 up to $15.7. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ironwood Pharmaceuticals's is 0.475. This would suggest that Ironwood Pharmaceuticals's shares are less volatile than average (for this exchange).

Ironwood Pharmaceuticals overview

Ironwood Pharmaceuticals, Inc. , a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc. , AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide.

Frequently asked questions

What percentage of Ironwood Pharmaceuticals is owned by insiders or institutions?
Currently 1.676% of Ironwood Pharmaceuticals shares are held by insiders and 105.288% by institutions. How many people work for Ironwood Pharmaceuticals?
Latest data suggests 267 work at Ironwood Pharmaceuticals. When does the fiscal year end for Ironwood Pharmaceuticals?
Ironwood Pharmaceuticals's fiscal year ends in December. Where is Ironwood Pharmaceuticals based?
Ironwood Pharmaceuticals's address is: 100 Summer Street, Boston, MA, United States, 02110 What is Ironwood Pharmaceuticals's ISIN number?
Ironwood Pharmaceuticals's international securities identification number is: US46333X1081 What is Ironwood Pharmaceuticals's CUSIP number?
Ironwood Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 46333X108